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~ Radlofrequency Catheter Using High Power Ablation 
F Phtlippon, L Blim, G, OHnra, M Gt l t~,  O¢~bec Heart Institute, Octet~c, 
Canada 
Radlofrequeno/ (RP) ¢:~theter ablation requires a tiscuo temperature (T~) 
~52~, Some ~ubstrates require either higher T ~ or more energy 1o achieve 
a stRcessful abl~tion cmd most g~ne~tom am limited 1o a maximum el fi0 W 
We sludted 904 o{mse(.~tiv~ ablations perlormed in Our labocaton/544 abla. 
tines were ~ usir~) a s ta~n; I  RF gene~ator (50 W max,, non thermistor) 
360 a~al~ns were ped~ wffh a high ~wer  genera(or (EPTI000XP~ 
0-450 W, It~m~l~tov) _ttsing T ~ mot,taring (se l at @O~_ 70 t'C) O! th~se 360 ab- 
la~ons (aft st~-'eSs~l), 13.5 r~u~ ~50 W Io ach~ev~ th~ targeted T ~, Th~ 
substrates were AVNRT ~,  ~W 35 (pgsterOSeptal IPS) 12, nght Slde~l 
5, left Sided 18). AVN !8 ar~l atnat fhtlter in 8 pts Five PS pathways were 
~'~rmncea nd 2 ~ght anteno~ and 1 PS palhways were pnor unsuccessful 
ablations The mean fluofo, t~me was 19 -, 14 m~n wtth a iT~an num~r 
el RF applications el 9. The effeCtwe tes~on required a mean o! 67 --_ t t  W 
(mean power set at B4 ~ 12 W) fo~ 50 ~ 17 sec to achieve a mean T *~ ot 
51 t 4 t'C (mean real. 1"- ach~.,ed 62 ~ 7 ~C me.an  60 ~1~) with a mean 
impedance el 126 ; 14 (.~. When tt~ mean effectwe les~on T ~ was :60 
~C, a "bonus" lesion wa~ apptte~ increasing the power untll the targeted "P' 
was obtained ~mng all the RF apphcat~n (bonus: mean: 62 5 ~ 16.4 W with 
median power set at 85 W) Air I~oceo'ures were successful and no coagufum 
foffaation was noted In con~a[~son, a 14% ta+lure fate was ob~ented m the 
544 ablations (:tone wdh th~ stan~lrd RF geuerato~ Them wa'~ no anhythm~a 
mcu.ence at a mean felfow41p of 9 months 
In Cot~,h.~ons: High power was re.(~J~fed tO obtasn the ~Slred T v in 38% 
Ol cases. Since ~ monitonng is required to use mo~e than 50 W (otherwise 
the output ~s ~ocked at 50 W), r{ sho~d be benel~ctal to use T ~ mon=tonng 
m aft cases with this g~'~retor. The ~mt~ai st.*tess rat"_ VS t~gher and prior 
ablabon failures can be done 5uccessfutb/. The influence of this technology 
on the feciJrrenCe rate wi~ need further S I~K~ 
3:00 
~ Electroanatomic o! Atrial and Junctional Mapping 
Tachy~a rdia 
E. Hoffmann, C Retthmann. P N~mmetmann. TRemp. S Ben-Hahn ~ 
G Ste~nbeck./I, fe~ Khmk t. K~mkum Gro,'~t,adern. LMU Munich, Germarn... 
' T~.  Ha#a. Israel 
Catheter abfabon of atnal and l~nctonal Iachycardla tAT JTi can be complex 
and brae c~nsumgng. The a~m of this Sl~dy was to determine the feaslbthty 
and safety of nonttuo~Oscop~c electroa.naremlc mapping and ablation m 21 
consecutn~e patients 4pts) w~th AT or JT t5 men t6 women, mean age 47 ; 
15 yeaisl 
ResiJRs e~ectrophys~ofogE study and CARTO mapping ot the nghI atnum 
t',as pedo~meO =n 24 tachycardtas and the mechanism cleterrn~ned as juno 
tional in 3 pts. incis~onal in 3 pts. reentran! in 4 pts, to(at kn 14 pts (4 left atnal). 
We created 24 maps wdh a mean of 79 ~ 48 different catheter pm;ltionS w~thln 
the nght atnum. The mapping procedure took 47 .- t6 rmn CARTe mapping 
cntena for focal tachyc~rd=a could be defined as radial impulse propagation 
away from the site of earhest achvation, clearly distant earliest and latest 
actntafion and a d~fterent achycard~a c~,,cle length (CL) and achvatton tvme 
(366 "~; 115 ms vs 94 ~ 30 ms) Reentry lachycardtas were charactenzed as 
close proximity el earhest and latest activ~f and a comparable fachycard~a 
CL and activation bme (~36 .* 44 ms vs 240 ~ 56 ms). The 8bfatlon ot the 
4 left AT was not attempted in the fiist ablabon session fn t50t  17 (88%) 
nght AT and 2 of 3 JT. ablat~en was pedormed successfully No complications 
occurred 
Conclustons: the wsuahzatlOn and 30 presentatron of the atrial achvabon 
sequence with the CARTe system allows the differentiation of tachycard~a 
mechanisms and the determination ot the suCCessful site of ablabon in nght 
atnal focal and junctional tachycardias 
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~True  Ablation of AV Nodal Reentry Using Anatomic 
Radiofrequency Current Guided by Intravascular 
Ultrasound 
W.W. Wassynger, D.D. Hodgkin, T.W Simmons. W.K Haisty. Jr.. 
G.H. Crossloy, DM. Fitzgerald. Bowman Gray School of Medicine. 
Winstod-Satem, N.C.. USA 
Radiofrequency (RF) ablation of the slow pathway of AV Nodal Reentry 
(AVNRT) is usually guided by fluoroscopic anatomy which shows the rel- 
ative location of a mapping catheter to reference catheters. Intravascular 
ultrasound (IVUS) provides precise anatomic detail of the tecuspid annulus 
end coronary sinus and may be useful for mapping and ablation procedures 
requiring ~nalem~c lesions Acoor(tmgly, tn s,xleen consecutive pat=eats with 
tVPiOal AVNRT an IVUS probe t6 2F. 12 MHz) was placed along the tncusp~d 
annulus RF ciJffonl was applied through an ablation ¢..atlletef lAG) pl~ced 
using IVUS m front of the o5 of the coronary sinus on the lncuspid annutu~ 
(500 FIgure) in al! 16 pts 5tow pathway conduction wa.~ ehmmated Suc 
ces~u! ablal~on was achmvod w'~h 1-7 RF pulses (me0~an, 2). Fk~omscop,c 
foc~tmn el RF pulses was mKt.Sop~al in 4 pfs and poStern-sept= ~n 6 pls 
despffe IVUS location o! the AC in the postemsepfat region m t0 plS 
Condu~ons: Selective slow pathway ablahon of AVNRT can be achmvea 
using IVUS to place anatom,c RF lesions Fluoroscopic !ocat~or ot the AC 
is tess accurate than IVUS Once validated, this technique could reduce 
~ad~ahon exposure and the numbm ot RF les~ons 
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1851-1~ Adenosine Inhibits Cardiac Expression of Tumor 
Necrosis Factor-alpha in the Failing Human Heart 
OR Wagner. C McT;eman. AM Fetdman Unwersdy ot PrttS~burgh. 
Pwttsburg~. P4. USA 
Background Tumor necros~s factor-alpha (TNF} has been ,mphcated ,n the 
path~enesL~ ot CHF We have prewously shown that adenosine mh~blts the 
hpopotysacchande (LPSl-mduCecl exWesston of TNF m rat card~omyocy~es 
and rat papdfary muscle The azm ot Ibis 5tu~ was to determine whether 
adenosine has the same effect m the tailing human head muscle 
Methods Trabeoular muscles were ~solated from the hearts of cardiac 
transplant reorients and stimulated with LPS (10 j,oJmlt TNF release was 
measured w~th enzyme linked immunosorb~nt assay Muscle sections were 
analyzed [mmunohtstochem~cally for the presence of TNF 
F/e~ults ~n contrast to healthy rat papdla~ muscte~ trabecular ,nusdes 
from tattrng human h.'~,arts released TNF m the absence of LPS (287 • 91 
pcj:'ml/g wet weight). However. addition of LPS induced a fudher 10-told in- 
crease =n TNF The adenosine A2 receptor agonist DF~IA (10 .M)  inhlbltnd 
the abdity of LPS to activate myocardial TNF by 94% (n = 7, p - 0.05) 
Iodotuberodin (10 ~, M), wh¢ch increases endogenous adenosine concenfra- 
lyon. also mh~bited TNF expressmn m frab~cular muscle by 99% (n = 7, p - 
005)  lmmunoh~stochemtsfry iclenf=fled the rnyocyte as a primary source of 
TNF m the tailing human heart 
Cortctus~On Adenosine can s~gntticantly diminish TNF levers m the tailing 
human heart and may pro~de a new pharmacologic approach =n CHF 
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~;'~-1-~ Increased Protein Kinase C Expression in Falling 
. . . . . . . . . .  Human Heart 
N 8owhng. T Esthdge, R Fouls. G. Song. R Reded. M. BnstOW, R. Walsh. 
H Sabbah. G Sandusky J M~zrahL G Gromo. C. Vlahos Ldl¥ Rose,Itch 
Labs. tn~an,~lrs. /N. USA 
Backaround The aim of the study was to determine protein klnase C 
¶PKC)-,~I and ,,,2 e~press~on =n lading and nontaflvng myocard, um to as- 
certain il re-expression of PKC-, , ts a marker of heart failure 
Methods: Explanted hearts of patients with td=opGth=c dilated cardlomy- 
opathy (DCM) or coronary artery disease (CAD) were examined for PKC-~ 
content by Western blot. m situ hybndization, tmmunostammg, and enzymatic 
activity, and compared with nontailed (NF) left ventncle tLV) from hearts ro- 
iected for transplant. 
Results: Western blots showed that PKC-;~ was s~gnificantfy increased m 
membrane fracbons of faded hearts (n = 12) compared to NF (n = 11) tr ~ t : 76 
7 vs. 49 ± 9 units. P - 004: t~2: 7B ! 9 vs. 52 : 4 units. P - 0 l 02 ; : ~e m 
were no differences beP, veen DCM and CAD faded hearts. Immunostam~ng 
204A AI{,";TRACI"S -. Oral JACC Fchnmry I~)ql'l 
with antibodies to PKC-/I1 and -/+2 was slight in NF myocyte, but intense in 
the myocytes of fallod LV, In situ hybridization revealed Increased expression 
ot PKC-ttl and/~2 mRNA in cardtomyocytos ot failed human heart tlssuo, 
Total PKC activity wee incroasod in membrane trectlonn from failed hoarts 
11219 ~ 188 v~, 609 ~ 171 pmol/mln/mg protein; tsllod va, NF; P • 0,05). 
LY333531, I~ aolectlve Inhibitor of PKC.tt, significantly decroaned PKC ~ctlvlty 
from failed he~rls by 24%, 
Concl~tslon~: PKC.II1 end .112 are elevated In tmled human heart, and 
inhibition of PKC.II may represent a novel therapeutic approach to henri 
tnlluro, 
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~ rowth Hormone Raals tanoo In Chrenl¢ Heart 
Failure 
SID, Ankor, M, Voltnrranl, C.D Ptlnt~m, P,A, PooIo-WII~on, 
C,J, Stmsburger, A,J,S, Co~ts, Cardiac Medicine, NHLI London, UK; Dept 
Of CnMiotolgy, Git,~f~¢l;lO, It~ly 
Acquired growth hormlDnlD (GH) rem~tanco occurs In t~evsro illness and 
cachaxta, and mrty explain ll~e different responses to OH in mlDent st~!d. 
~ns el p~,lient~l with chronic hlDrlrt niluro (CHF), 
In 72 CHF p~tianf~ (~ge 61 t ly ,  po~k VO: 16,5 ~ 0,7 ml/kglmtn) 
and ~0 healthy contml~ ([Con] ~ t 2y, p ,. 007) the L3H - IGF.I axis 
was Sh, ldtod tn ml~lilDn to IGF binding protein 3 (IGFBP-3) and GH.binding 
protein (GH.BP) (cenlrul~ vs CHF dilferenct~s = NS), The CHF patients were 
sub-dovidod ~CCordmg to cacholDti~ (tel, • 7,5% wolgbt loss over ~ 6 months) 
or non.c~ch0ctic (no) ~fate, The iooIGF.I/GH ratio (O AM) w~s c~lculatod 
~ Index oi GH sensitivity, and was round to correlate well with mean OH 
overnight levet.'~ 111 CHF patients', blood samples for 8 hm, eve~ 20 ram, r = 
-0,60, p m 0.05), and mlDan overnight IoglGF-ItGH ratio (r ,. 072, p m 0,01 ). 
Cor~ n¢CHF OCt'iF nCCHF ~,~. cCHF ~,..s cCHF ~,,'s 
o + ~6 n ~ ~1 n = 21 Co~ tPf Con (pf ncCHF ttrt 
tet,~l GH tngtml) t~ID3 1~t03 ~3113 N~ . 0 01DOt . 0 I0001 
intact GH (ng!m!t 05101 04!['11 t6tOS NS (~ IDnz~r ID 0017 
tGF.t (n&~'T~t) 1511~ 15SIS 12410 N~ 0169 000 
log IGF,I/GH ~ 7~ID~ 20~ID 1 17~0~ NS ID I60162 00001 
IOFBP-3 (+,g;ml) 36+ID I 37+01 31~0~ N,~ ID I012 e012 
GH.BP (pmolflt 8.~2 ~B3 950~ S4 6107 t6,t NS 006 O IDI047 
mo~n :t SEM; NS = p 0 20 Sample tmw ID AM 
Correlations: log IGF-I/GH vs %ideal weight (Con: r = 0,.23, p = NS: CHE 
r = 0.54, p - 0.00Or), and t..s GH-BP (Con: r = 079; CHF: r = 0,61, both p - 
0.0001:nc:r=0,50, p- 0,01; c: r = 0.68, p 0001). 
Cnchectic patients w~th CHF show the b~ochom~cal Ioaturos et acquired 
GH resistance possibly duo to a down regutabon of Gtt roceptom The 
presence at GH resistance may ~nlluonce the response to GH therapy and 
should be assessed peer te tro~Hment 
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~ T h e  Growth Hormone Secretagogue Hexarelln 
Improves Cardlsc Function In Rats After 
Experimental Myocardlal Infarct ion 
A, Tivosten, E. Botlano, V. Kujacic, K. Caidahl, X.Y. Sun, T. Hedner, 
A Hjatmarson, B-A Bengtsson, J Isgnnrd, Re.~eamh Center of 
Endocnnology and Metabolism, Sahlgrenska University Hospital, Stt~ttlen 
Background; Accumulating evidence indicate that growth hormone (GH) can 
enhance cardiac performance both tn rats after experimental myocardial 
infarction (MI) and in patients with congestive heart failure. Hexarelin is 
one of several synthetic compunds with capacity to stimulate GH secretion 
in animals and humans. The aim of the ?r:sent study was to investigate 
if administration ef Hexarelin could improve cardiac function in rats after 
oxpenmontal MI. 
Methods: Male rats were treated for two weeks with either Hexarolin in 
a dose of 5 or 50 ~9 • kg ~, recombinant human GH (rhGH) in a dose 
of 1 mg , k9 ~ or saline injected s.c twice daily four weeks after ligation 
of the left coronary artery Intact rats were used as controls. Transthoracic 
echocardiography was performed before and alter the treatment period. 
Results: Stroke volume (SV) was increased 49% 10% by rhGH, 53% ~: 
16% by Hexarelin 10 t,g kg ~ . day ~. and 55% = 2~% by Hexarolin 100 ~g 
kg ~ day ~, (p .  0,05 vs baselinc). Ca,disc output (CUt was increased 
62% ± 21% by rhGH, 48% ± 19°,o by Hexarettn 10 I~g kg ~ • day ~ and 
51% :~ 13% by Hoxaretin 100 ,,g. kg t • day ~, There were no effects on 
SV and CO in the saline treated groups. 
Conclusion: HexarlDlin improves cardiac pedormance to a similar extent 
as exogenously administered rhGH in rats after experimental myocardial 
infarction. This may have clinical =mptications if beneficial effects can also be 
obtained in patients with congestive heart failure. 
3:00 
~']  Renal and Effects of Growth Hemodynamlc 
Hormone Treatment In Experimental Heart Failure 
R. Witlonbrock, I, Paget, M. Schauermann, K,-J, Osforziol. R. Dielz 
Franz.Voll~.KIInik, Berlin, Germany 
Chronic growth hormone (GH) treatment is a now approsch for the Ihorapy 
of heart failure. We nn~lyzod whether c~trdlac and mnst function could I~ 
improved by chronic applie~tion of GH in experimental heart fmlura, Manifest 
henri tmluro was induced by .~ largo ~ortocavctl shunt in male Wist~r rats 
which wore tra~ted with recombinant human GH (2 mgtd~y s,¢,) for 30 
dtWs, We ~nyi~tod ron~t oxcmton/lungfish by g~ing rrmtabolio genes ~ed 
measured cardiac pressures ~nd contractility, 
Rats frosted with GH developed ,1 significant higher body weight a!msdy 
attar 0 d~ys of treatment, Allot 30 d~ya, the GH treated rats weighed 333 
t g vs, 305 .t: 0 g in plneobo trar~ted shgflt~ rats (p • 0,01), The tatative 
heart weight increased in situated rats from 319 t ? to 583 ~ 40 mg!100 
g, compared 1o sham operated controls, but was net in l lue~ by GH 
tm~lma_nl C,rdiac onddinslolic pressures were o!evuted in ~hunted trats 
compared to sham.operated controls, but worn not medilied by GH Slm=!a~, 
catdialD contractility (dPldt) wa~ Iowor in shunted rats (4820 :~ 210 vs, 5400 
t 433 mmHgisoc, p - 0,05) and was 001 improved by OH therapy Water 
intake w~s net different bolweon GH. and placebo treated shunted an*mats 
Wdte~ aed sodium excretion, however, was enhancer'1 by GH: natnurosis 
Increased Item 154 , 0.06 to 2,01 ~ 0.10 mmol;d (p - 005) and diurests 
from 17,4 t P,01023,1 t 3.0mild(p- 0,05). 
Our results suggest thai chronic treatment with growth hormone m=ght not 
improve cardiac 16nction in this mode! of heart lailure but seems to have a 
beneficial effect on water and sodium homeostasis, 
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L~51~ 17/3.Estred,ol Protects  Against ,he Oevelopment ot 
Pressure Overload Cardiac Hypertrophy in Rats 
L.-R Gas, B -Q Zhu. Y.-P Sun, RE. Sievets. TM. Chou. R Lee, 
K. Chatteqoe. K. Sudhff. Universffy of Cal#ornra...~m Francisco. CA, USA 
Cardmc hypertrophy shows gender-based differences with markedly h~gher 
mortality in men The irdlueece el estrogens on cardiac hypertrophy is poorly 
understood. Thcs study examined the protective effect o! 17p-estradtol rE2) 
against the development o1 cardiac hypertmpby induced by abdominal aortic 
banding for 6 weeks. One hundred 8-wk old male (M) and evanectomlzed 
tamale iF) Spraguo Dawley rats were randomized to sham-operated iS). 
banding + placebo (P) and banding + E2 rE2, 10 mg slow release pellets 
implanted 48 h before surgery) groups. We measured carotid and left ventnc- 
ular systolic (CSP, LVSP, mmHgl and diastolic pressure (COP. LVDP). ratio ot 
left venbicular woight to body weight (LVWIBW. m~}'g). LV : dp/dt (mmH&'s) 
and LV wall thmkness (LVW.T. mmL and cardmc myosin boaW chain (MHC) 
mRNAs by Nodhem blo1 analysis. 
Group LVW~BW CSP LVSP LV + dp/dt LVW+T 
P(Mt 28±01 177.'11 127~7 4573 ~ 169 440e2 
E2 tM) 23 t ID t' 117 ~ 4" 95 t 4" 3372 : 201" 36 : 01" 
P tFt 30 ~: O r r55 t 3 99 ~ S 4406 : 232 6 t t 02 
E2 iF) 2 5 t so" 118 ~ 3" 79 t 3" 3624 t 148" 3 7 : 0 1" 
Moan ~ SEM. ' p - O I05 oompamd with group P 
E2 significantly attenuated hypertension and reduced felt ventricular mus- 
cle mass in both male and ovenectomized female rats. Further. E2 but not P 
decreased expression of/~-MHC mRNA. 114.3% in male: 152% in female: 
both P .: 0.05) but increased .-MHC mRNA (9.8% in male: 11 3% in female: 
both P • 0.05). 
Conclusions: 17/~-Est,adiol prevents the development of hypertension 
and cardiac hypertrophy in rats with experimental hypertension. 
